Co-Authors
This is a "connection" page, showing publications co-authored by CHARLES LU and NAIFA L BUSAIDY.
Connection Strength
0.429
-
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1672-1680.
Score: 0.062
-
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271.
Score: 0.061
-
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.
Score: 0.055
-
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2022 08; 6:e2100504.
Score: 0.053
-
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.
Score: 0.046
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.043
-
Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017 07; 39(7):1291-1295.
Score: 0.037
-
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681.
Score: 0.036
-
Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 01; 27(1):81-87.
Score: 0.036